Woodline Partners LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 135,036 shares of the company's stock, valued at approximately $991,000. Woodline Partners LP owned 0.10% of Vir Biotechnology at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in VIR. Point72 Asia Singapore Pte. Ltd. bought a new position in Vir Biotechnology in the 4th quarter valued at $42,000. SBI Securities Co. Ltd. purchased a new stake in shares of Vir Biotechnology during the fourth quarter valued at $60,000. PNC Financial Services Group Inc. grew its holdings in shares of Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after purchasing an additional 1,999 shares during the last quarter. KBC Group NV increased its stake in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after buying an additional 5,177 shares during the period. Finally, CIBC Asset Management Inc purchased a new position in Vir Biotechnology in the 4th quarter worth about $74,000. Institutional investors own 65.32% of the company's stock.
Vir Biotechnology Stock Performance
Vir Biotechnology stock traded up $0.43 during mid-day trading on Thursday, reaching $5.19. 1,904,301 shares of the company were exchanged, compared to its average volume of 1,388,246. The firm has a market cap of $717.46 million, a P/E ratio of -1.32 and a beta of 1.36. The business has a fifty day moving average of $5.58 and a 200 day moving average of $7.59. Vir Biotechnology, Inc. has a 12-month low of $4.32 and a 12-month high of $14.45.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $3.03 million during the quarter, compared to analysts' expectations of $8.59 million. During the same quarter last year, the firm earned ($0.48) EPS. Vir Biotechnology's revenue for the quarter was down 94.6% on a year-over-year basis. Sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.
Insider Activity at Vir Biotechnology
In related news, CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the transaction, the chief executive officer now directly owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Several research firms have issued reports on VIR. The Goldman Sachs Group lowered their price objective on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. HC Wainwright reaffirmed a "buy" rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday, February 28th. Barclays boosted their price target on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Finally, Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of Vir Biotechnology in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.86.
Read Our Latest Stock Analysis on Vir Biotechnology
Vir Biotechnology Profile
(
Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
See Also
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
